Search

everythinglearnresearchcommunity

for

Search:↓

Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.

Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.

Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.

Bempikibart may help regrow hair in people with alopecia areata.

Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.

Upadacitinib effectively treats severe alopecia areata and is safe.

Upadacitinib may effectively treat resistant lichen planopilaris.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

Baricitinib is effective and safe for treating alopecia areata.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.

EGFR inhibitors in breast cancer treatment can cause serious skin issues affecting patient quality of life.

AD198 is more effective than doxorubicin in stopping certain dog cancer cells.

Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.

Combining ATRA with TPO-RA effectively stabilizes platelet counts in ITP patients.